TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16495262

Group type: EXPERIMENTAL
Intervention: Oritavancin 5 mg/kg/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oritavancin 6.5 mg/kg/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oritavancin 8 mg/kg/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oritavancin 10 mg/kg/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oritavancin
Number of subjects: 55
Study: 12626461

Group type: EXPERIMENTAL
Intervention: Detection of DEN-specific IgM in saliva
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Detection of DEN-specific IgA in serum
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Detection of DEN-specific IgA in saliva
Number of subjects: 147

Group type: COMPARATOR
Intervention: Detection of DEN-specific IgM in serum
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Detection of DEN-specific salivary IgM
Number of subjects: 147
Study: 11151876

Group type: EXPERIMENTAL
Intervention: Mesalazine therapy for 8 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mesalazine therapy
Number of subjects: 20
Study: 9174316

Group type: EXPERIMENTAL
Intervention: 200 microg epinephrine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2 microg/kg clonidine
Number of subjects: 45

Group type: COMPARATOR
Intervention: 1 mg/kg 5% meperidine alone
Number of subjects: 45
Study: 8249505

Group type: EXPERIMENTAL
Intervention: Endocervical brush
Number of subjects: 203

Group type: COMPARATOR
Intervention: Cotton swab
Number of subjects: 203
Study: 29750574

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training combined with high-intensity interval training (AT-HIIT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resistance training combined with high-intensity interval training (RT-HIIT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 23
Study: 27198129

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (LOW) with hemoglobin trigger of 7 g/dL
Number of subjects: 90

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (HIGH) with hemoglobin trigger of 8 g/dL
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both arms (LOW and HIGH)
Number of subjects: 90
Study: 25555523

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) for 30 minutes every 8 hours starting on postoperative day 1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no TENS treatment)
Number of subjects: 50
Study: 23733779

Group type: EXPERIMENTAL
Intervention: FAC-wP (Fluorouracil, Doxorubicin, Cyclophosphamide followed by weekly Paclitaxel)
Number of subjects: 1925

Group type: COMPARATOR
Intervention: FAC (Fluorouracil, Doxorubicin, Cyclophosphamide)
Number of subjects: 1925

Group type: EXPERIMENTAL
Intervention: FAC-wP
Number of subjects: 1925

Group type: COMPARATOR
Intervention: FAC
Number of subjects: 1925
Study: 20492852

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) + SSRI
Number of subjects: 150
Study: 19064840

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 170

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 170
Study: 16939737

Group type: EXPERIMENTAL
Intervention: Low hemoglobin transfusion threshold (n = 223)
Number of subjects: 451

Group type: COMPARATOR
Intervention: High hemoglobin transfusion threshold (n = 228)
Number of subjects: 451
Study: 12559680

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study: 11129765

Group type: EXPERIMENTAL
Intervention: Specialized home care intervention provided by advanced practice nurses (APNs) for 4 weeks, including three home visits and five telephone contacts.
Number of subjects: 375

Group type: COMPARATOR
Intervention: Usual follow-up care in an ambulatory setting.
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Specialized home care intervention for late stage patients.
Number of subjects: 375

Group type: COMPARATOR
Intervention: Usual care for late stage patients.
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Specialized home care intervention overall.
Number of subjects: 375

Group type: COMPARATOR
Intervention: Usual care overall.
Number of subjects: 375
Study: 9108847

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine combined with oral poliovirus vaccine
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: MRC‐5 cell‐derived inactivated poliovirus vaccine as a combined injection
Number of subjects: 425

Group type: COMPARATOR
Intervention: Live attenuated poliovirus vaccine
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (MRC‐5 or Vero cell-derived)
Number of subjects: 425
Study: 10149176

Group type: EXPERIMENTAL
Intervention: GSL + Ursodiol (Actigall)
Number of subjects: 661

Group type: COMPARATOR
Intervention: GSL Only
Number of subjects: 661
Study: 4035330

Group type: EXPERIMENTAL
Intervention: 25 mg of amitriptyline (AT) per day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg of amitriptyline (AT) per day
Number of subjects: 12
Study: 31352795

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg via nasogastric tube after declaration of brain death
Number of subjects: 84

Group type: COMPARATOR
Intervention: No simvastatin treatment
Number of subjects: 84
Study: 29300975

Group type: EXPERIMENTAL
Intervention: hMG + DYG
Number of subjects: 516

Group type: COMPARATOR
Intervention: hMG + MPA
Number of subjects: 516
Study: 27908347

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: NT-proBNP reduction to ≤1,000 pg/ml
Number of subjects: 1292
Study: 25386965

Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 599
Study: 22402955

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 15
Study: 20438009

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (60 minutes, supervised, three times per week for 12 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sedentary lifestyle (Control group)
Number of subjects: 43
Study: 19075279

Group type: EXPERIMENTAL
Intervention: GLSG treatment (1996 to 2004)
Number of subjects: 520

Group type: COMPARATOR
Intervention: KLSG treatment (1975 to 1986)
Number of subjects: 520
Study: 15840776

Group type: EXPERIMENTAL
Intervention: Professionally applied fluoride gel (1% sodium fluoride, applied semi-annually)
Number of subjects: 594
Study: 12588354

Group type: EXPERIMENTAL
Intervention: Short and intensive chemotherapy (most recent protocol)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Previous trials (less intensive chemotherapy)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Patients >= 15 years old
Number of subjects: 470

Group type: COMPARATOR
Intervention: Patients < 15 years old
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: M2/M3 bone marrow involvement
Number of subjects: 470

Group type: COMPARATOR
Intervention: M1 bone marrow involvement
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: LDH >= 500 IU/l
Number of subjects: 470

Group type: COMPARATOR
Intervention: LDH < 500 IU/l
Number of subjects: 470
Study: 10507207

Group type: EXPERIMENTAL
Intervention: Opalescence
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nite White
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 30% hydrogen peroxide solution
Number of subjects: 15
Study: 8594265

Group type: EXPERIMENTAL
Intervention: Intravenous T(3) (0.8 microg/kg followed by 0.12 microg.kg(‐1).h(‐1) for 6 hours)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Dopamine (positive control, 5 microg.kg(‐1).min(‐1) for 6 hours)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 1768545

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.2 mg sublingually
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6803191

Group type: EXPERIMENTAL
Intervention: Continuous nasogastric feedings with phenytoin suspension 300 mg per day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Discontinued continuous nasogastric feedings
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Continuous tube feedings started with phenytoin suspension 300 mg per day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Single oral dose of phenytoin suspension alone
Number of subjects: 25
Study: 30636649

Group type: EXPERIMENTAL
Intervention: Minding the Baby (MTB) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30817597

Group type: EXPERIMENTAL
Intervention: Bazhengsan formula (BZSF) and ceftriaxone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ceftriaxone alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (BZSF + ceftriaxone and ceftriaxone alone)
Number of subjects: 40
Study: 27939319

Group type: EXPERIMENTAL
Intervention: Lactobacillus kefiri LKF01 (DSM32079)
Number of subjects: 20
Study: 26519538

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24345827

Group type: EXPERIMENTAL
Intervention: LYM‐X‐SORB (LXS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Isocaloric placebo comparison supplement
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both interventions (LXS and placebo)
Number of subjects: 58
Study: 21939490

Group type: EXPERIMENTAL
Intervention: Contrast-tuned imaging (CnTI)
Number of subjects: 150
Study: 19512861

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric antrum
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric body
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric fundus
Number of subjects: 54
Study: 17889357

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 16055263

Group type: EXPERIMENTAL
Intervention: Paroxetine medication for 8 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study: 12104059

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Amlodipine
Number of subjects: 0
Study: 10425807

Group type: EXPERIMENTAL
Intervention: 7% blackcurrant drink (0.49% carbohydrate)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10% blackcurrant drink (0.65% carbohydrate)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mixed citrus drink (4.5% carbohydrate)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 10% sucrose (control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 10% sorbitol (control)
Number of subjects: 24
Study: 7589764

Group type: EXPERIMENTAL
Intervention: 6 mg dihydroergocristine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20 mg dihydroergocristine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 2297463

Group type: EXPERIMENTAL
Intervention: 240 mg BN 52063 p.o.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.4 mg BN 52063 inhalation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 240 mg BN 52063 p.o. (EIA study)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 mg BN 52063 inhalation (EIA study)
Number of subjects: 10
Study: 6971551

Group type: EXPERIMENTAL
Intervention: Ergocalciferol 5000 units daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal dietary vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet restricted in vitamin D (less than 50 units)
Number of subjects: 0
Study: 31200775

Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation (gentle mechanical vibrations administered during 3 h at night for 3 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham (placebo effect controlled using identical instruments)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation
Number of subjects: 63
Study: 28732314

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 25867798

Group type: EXPERIMENTAL
Intervention: Triple-dose Gadolinium (TdGd) administration
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Less frequent gadolinium administration
Number of subjects: 75
Study: 24112999

Group type: EXPERIMENTAL
Intervention: Venlafaxine IR, 150 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 21377076

Group type: EXPERIMENTAL
Intervention: PCA group with continuous background morphine infusion (Group 2; n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCA group without continuous background morphine infusion (Group 1; n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 19289979

Group type: EXPERIMENTAL
Intervention: Home treatment by community health workers (CHWs) using injectable antibiotics for very severe disease.
Number of subjects: 8474

Group type: COMPARATOR
Intervention: Treatment by qualified medical providers.
Number of subjects: 8474

Group type: COMPARATOR
Intervention: No treatment or treatment by unqualified providers.
Number of subjects: 8474

Group type: COMPARATOR
Intervention: Home treatment by CHWs compared to no treatment/untrained providers.
Number of subjects: 8474

Group type: COMPARATOR
Intervention: Treatment by qualified providers compared to no treatment/untrained providers.
Number of subjects: 8474

Group type: COMPARATOR
Intervention: Neonates with convulsions.
Number of subjects: 8474

Group type: COMPARATOR
Intervention: Neonates with chest in-drawing.
Number of subjects: 8474

Group type: COMPARATOR
Intervention: Neonates with temperature <35.3 degrees C.
Number of subjects: 8474

Group type: COMPARATOR
Intervention: Neonates with unconsciousness.
Number of subjects: 8474
Study: 18065585

Group type: EXPERIMENTAL
Intervention: Fish oil (3 g/d, 1.8 g n-3 PUFAs)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (paraffin oil)
Number of subjects: 27
Study: 15367054

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Peer and partner support
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nondirective counseling
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Relaxation/massage therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Infant sleep interventions
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Infant-mother relationship therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Maternal exercise
Number of subjects: 21
Study: 10706235

Group type: EXPERIMENTAL
Intervention: Kudzu root extract 1.2 g twice daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9305414

Group type: EXPERIMENTAL
Intervention: Ritanserin 2.5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ritanserin 10 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ritanserin (both doses)
Number of subjects: 15
Study: 1467416

Group type: EXPERIMENTAL
Intervention: Trometamol Phosphomicine (TP) - single oral dose
Number of subjects: 150

Group type: COMPARATOR
Intervention: Pipemidic Acid (PA) - 400 mg twice a day for 5 to 7 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Norfloxacine (NFX) - 400 mg twice a day for 5 to 7 days
Number of subjects: 150
Study: 6096241

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29578169

Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 76
Study: 27026584

Group type: EXPERIMENTAL
Intervention: Academic detailing plus audit and feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Audit and feedback alone
Number of subjects: 0
Study: 1424409

Group type: EXPERIMENTAL
Intervention: Placebo after 50 mg atenolol daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study: 22492697

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin 100 mg/m² day 1 + 5-FU 1000 mg/m² day 1-5) followed by irradiation for complete responders
Number of subjects: 202

Group type: COMPARATOR
Intervention: Surgical approach (total laryngectomy with partial pharyngectomy and neck dissection, followed by irradiation)
Number of subjects: 202
Study: 21235067

Group type: EXPERIMENTAL
Intervention: Deep needling (DN) of ST 25
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Shallow needling (SN) of ST 25
Number of subjects: 95

Group type: COMPARATOR
Intervention: Medication group (Lactulose, 20-30 mL/d)
Number of subjects: 95
Study: 18179320

Group type: EXPERIMENTAL
Intervention: Stereotype threat conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interracial interactions conceived as learning opportunities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conscious awareness of stereotype threat
Number of subjects: 0
Study: 16873930

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - Prempo (0.625 mg conjugated estrogen and 2.5 mg medroxyprogesterone acetate)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Postmenopausal women
Number of subjects: 98

Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 98
Study: 12845587

Group type: EXPERIMENTAL
Intervention: Test formulation of stavudine (40 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of stavudine (40 mg)
Number of subjects: 24
Study: 10613385

Group type: EXPERIMENTAL
Intervention: Tactaid II+
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tactaid 7
Number of subjects: 8
Study: 8876577

Group type: EXPERIMENTAL
Intervention: Continuous infusion of bupivacaine hydrochloride for 72 hours postoperatively
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal saline solution for 72 hours postoperatively (Control Group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous infusion of bupivacaine hydrochloride
Number of subjects: 21
Study: 1676251

Group type: EXPERIMENTAL
Intervention: IMREG-1
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 225252

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 50 micrograms + levonorgestrel 250 micrograms (50/250)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 50 micrograms + levonorgestrel 125 micrograms (50/125)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 30 micrograms + levonorgestrel 150 micrograms (30/150)
Number of subjects: 75
Study: 30391656

Group type: EXPERIMENTAL
Intervention: Patient report of goals-of-care discussion
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Clinician report of goals-of-care discussion
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: EHR documentation of goals-of-care discussion
Number of subjects: 494

Group type: COMPARATOR
Intervention: Clinician report and EHR documentation of goals-of-care discussion
Number of subjects: 494
Study: 28230252

Group type: EXPERIMENTAL
Intervention: Ganaxolone 1,500 mg/day
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 25842384

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 254

Group type: COMPARATOR
Intervention: Health information control
Number of subjects: 254
Study: 23863208

Group type: EXPERIMENTAL
Intervention: Cycloferon + Lamivudin for 48 weeks
Number of subjects: 647

Group type: COMPARATOR
Intervention: Lamivudin + Placebo for 48 weeks
Number of subjects: 647
Study: 20682597

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 21
Study: 19441604

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate and salmeterol combination via hydrofluoroalkane metered-dose inhaler
Number of subjects: 725

Group type: COMPARATOR
Intervention: Salmeterol alone
Number of subjects: 725

Group type: COMPARATOR
Intervention: Fluticasone propionate alone
Number of subjects: 725

Group type: COMPARATOR
Intervention: Placebo via traditional chlorofluorocarbon metered-dose inhaler
Number of subjects: 725
Study: 17242269

Group type: EXPERIMENTAL
Intervention: Imaging-guided percutaneous core needle biopsy
Number of subjects: 125
Study: 16858238

Group type: EXPERIMENTAL
Intervention: Transoesophageal cardioversion (TOC) with a step-up protocol of 30, 50, 70 and 100 J
Number of subjects: 210

Group type: COMPARATOR
Intervention: Transthoracic cardioversion (TTC) with a step-up protocol of 70, 100, 120 and 150 J
Number of subjects: 210
Study: 14654643

Group type: EXPERIMENTAL
Intervention: High-impact, circuit-based, jumping intervention (10 minutes, 3 times a week) over 2 school years
Number of subjects: 32
Study: 10418886

Group type: EXPERIMENTAL
Intervention: 14-session face-to-face intervention emphasizing abstinence and safer sex
Number of subjects: 515
Study: 7487795

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methohexitone
Number of subjects: 32
Study: 1706903

Group type: EXPERIMENTAL
Intervention: i.m. injection of 0.5 ml 'Influmun' vaccine from SSW Dresden/GDR
Number of subjects: 350

Group type: COMPARATOR
Intervention: enteric-wated capsules containing approximately 60 micrograms hemagglutinin of all three virus strains
Number of subjects: 350
Study: 86665

Group type: EXPERIMENTAL
Intervention: surgical treatment
Number of subjects: 768

Group type: COMPARATOR
Intervention: medical treatment
Number of subjects: 768
Study: 28691550

Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ERP) therapy for OCD, 4 weeks duration
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 44